QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
GENCURIX is the first development partner under QIAGEN's QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics.
The new partnership combines QIAGEN's QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX's expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through QIAGEN's Partnering Program.
'The QIAcuityDx Partnering Program is designed to enable the generation of a broad menu of IVD assays on the platform,' said Jonathan Arnold, Vice President and Head, Partnering for Precision Diagnostics at QIAGEN. 'The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS. We look forward to working with GENCURIX within this promising partner program.'
'This strategic partnership with QIAGEN represents a major inflection point for expanding our oncology molecular diagnostic technologies into the global market,' said Sang Rae Cho, CEO at GENCURIX. 'We are confident that the synergy between our diagnostic content and QIAGEN's platform will lead to global-standard precision cancer diagnostic solutions.'
The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx, which is a member of the QIAcuity family of digital PCR systems that reached at the end of 2024 more than 2,700 cumulative placements since launch. These menu initiatives for clinical applications will leverage this installed base as well as build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, and complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform at geneglobe.qiagen.com.
GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests The QIAcuityDx Four platform delivers a scalable and high-performance digital PCR solution for clinical laboratories. As global adoption of digital PCR grows, it is increasingly recognized as a complementary method to qPCR and NGS—particularly in oncology, infectious diseases, and rare genetic disorders. Through the QIAcuityDx Partnering Program, QIAGEN is opening its platform to third-party developers, encouraging innovation in order to offer laboratories a continuously expanding range of validated diagnostic tests.
GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. GENCURIX, as the legal manufacturer of the assays, will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide.
By enabling third-party development, QIAGEN is addressing the growing demand for broader access to high-precision and cost-efficient diagnostic assays. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support.
For more information about the QIAcuityDx Partnering Program please visit: www.qiagen.com/us/applications/digital-pcr-mdx/partnering.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
About GENCURIX
GENCURIX Inc. is a molecular diagnostics company based in Seoul, South Korea, focused on developing dPCR-based diagnostics and liquid biopsy platforms. Its products include GenesWell™ BCT, a breast cancer prognostic test, and Droplex™, a diagnostic assay series for companion and stratification testing in multiple cancer types. For more information, visit www.gencurix.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Investors in Civeo (NYSE:CVEO) have seen stellar returns of 166% over the past five years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stock. One great example is Civeo Corporation (NYSE:CVEO) which saw its share price drive 147% higher over five years. Also pleasing for shareholders was the 22% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 16% in 90 days). So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because Civeo made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. In the last 5 years Civeo saw its revenue grow at 6.1% per year. That's a pretty good long term growth rate. We'd argue this growth has been reflected in the share price which has climbed at a rate of 20% per year over in that time. Given that the business has made good progress on the top line, it would be worth taking a look at the growth trend. When a growth trend accelerates, be it in revenue or earnings, it can indicate an inflection point for the business, which is can often be an opportunity for investors. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). If you are thinking of buying or selling Civeo stock, you should check out this FREE detailed report on its balance sheet. What About The Total Shareholder Return (TSR)? Investors should note that there's a difference between Civeo's total shareholder return (TSR) and its share price change, which we've covered above. Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. Dividends have been really beneficial for Civeo shareholders, and that cash payout contributed to why its TSR of 166%, over the last 5 years, is better than the share price return. A Different Perspective Civeo shareholders are up 1.7% for the year. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 22% per year for five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Civeo you should be aware of. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Newmont (NEM) Jumps 6.89% on Better Income, Dividend News
We recently published . Newmont Corporation (NYSE:NEM) is one of the best-performing stocks on Friday. Newmont rallied for a second day on Friday, jumping 6.89 percent to close at $65.75 apiece as investor sentiment was bolstered by an impressive earnings performance and news that it will distribute cash dividends to its shareholders. In its earnings release, Newmont Corporation (NYSE:NEM) said net income attributable to shareholders in the second quarter of the year jumped by 142 percent to $2.06 billion from $853 million in the same period last year. Adjusted EBITDA also rose by 52 percent to $2.997 billion from $1.966 billion. Additionally, attributable gold production ended lower by 8 percent during the period at 1.48 million ounces versus 1.61 million ounces year-on-year, driven by the previously announced closing of non-core asset sales. However, the closure was partially offset by higher production from four other sites. Copyright: tomas1111 / 123RF Stock Photo The average realized gold price increased by 41 percent to $3,320 from $2,347 year-on-year. In other news, Newmont Corporation (NYSE:NEM) also declared a $0.25 cash dividend to each common shareholder as of September 4. The dividends will be payable on September 29. While we acknowledge the potential of NEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Hawaii American Water Granted New Rates by Hawaii Public Utilities Commission
HONOLULU--(BUSINESS WIRE)--The Hawaii Public Utilities Commission (HPUC) has approved new wastewater rates for Hawaii American Water's Hawaii Kai, Mauna Lani, and Waimea service areas. The company's rate request was filed on August 5, 2024, and was primarily driven by over $40 million in local infrastructure upgrades in all three districts. The new rates reinforce the company's commitment to replace aging infrastructure, provide safe and reliable service, comply with environmental regulations and support infrastructure improvements for treatment plants, collection systems and pump stations. 'We are committed to making necessary infrastructure investments that allow us to continue providing safe and reliable wastewater services, while also enhancing the systems for long-term sustainability, resiliency and environmental protection,' said Lee Mansfield, Senior Manager Operations, Hawaii American Water. 'Our approach to consistent and efficient investment balanced with managing costs helps us deliver reliable and affordable service to our customers.' New rates are expected to be effective in early August 2025. The typical single-family customer in Hawaii Kai will see a monthly rate increase of approximately $4. For our Big Island operations at Mauna Lani and Waimea the typical single-family customer will see a rate increase of approximately $18 to $25 per month. The last rate adjustments were September 2003 for Mauna Lani operations and January 2011 for Waimea operations. The company last filed a rate case for the Hawaii Kai system in 2021. Customers will receive information about the new rates on their Hawaii American Water bill. Information will also be available on the company's website under Customer Service Billing, Your Wastewater Rates. About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. About Hawaii American Water Hawaii American Water, a subsidiary of American Water, provides high-quality wastewater services to approximately 30,000 people. AWK-IR
